Comprehensive Updates in the Role of Imaging for Multiple Myeloma Management Based on Recent International Guidelines

Korean J Radiol. 2021 Sep;22(9):1497-1513. doi: 10.3348/kjr.2020.0886.

Abstract

The diagnostic and treatment methods of multiple myeloma (MM) have been rapidly evolving owing to advances in imaging techniques and new therapeutic agents. Imaging has begun to play an important role in the management of MM, and international guidelines are frequently updated. Since the publication of 2015 International Myeloma Working Group (IMWG) criteria for the diagnosis of MM, whole-body magnetic resonance imaging (MRI) or low-dose whole-body computed tomography (CT) and 18F-fluorodeoxyglucose positron emission tomography/CT have entered the mainstream as diagnostic and treatment response assessment tools. The 2019 IMWG guidelines also provide imaging recommendations for various clinical settings. Accordingly, radiologists have become a key component of MM management. In this review, we provide an overview of updates in the MM field with an emphasis on imaging modalities.

Keywords: 18F-FDG PET/CT; Diagnosis; Low-dose whole-body CT; Multiple myeloma; Treatment response; Whole-body MRI.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Fluorodeoxyglucose F18
  • Humans
  • Magnetic Resonance Imaging
  • Multiple Myeloma* / diagnostic imaging
  • Positron Emission Tomography Computed Tomography
  • Positron-Emission Tomography
  • Radiopharmaceuticals
  • Whole Body Imaging

Substances

  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18